Search results for: 'formulation components shift'

This analysis provides an overview and advancements in the oral solid dosage formulation industry, including an evaluation of the current industry scenario, competitive landscape, and regulatory landscape. The scope of the analysis is global, focusing on North America (NA), Europe, Asia-Pacific (APAC), the Middle East, and Latin America (LATAM). It...

This market insight provides a first-of-its-kind analysis of market sizing and revenue forecasts through 2016 for the prevalent Ebola virus. The number of people infected nears 10,000 globally, and the Centers for Disease Control and Prevention (CDC) and World Health Organization (WHO) have deemed this the worst outbreak due to the death toll neari...

05 Feb 2021  |  North America  |  Market Research

Shifting Spotlight from Product- to Value-based Outcomes Intensifies Growth in the US Real-world Evidence IT Solutions Market

Early-stage R&D and Commercial Applications Fuel the Growth Pipeline

Infographics

×

The US healthcare industrys transition to a patient-centric model is moving rapidly with focus on outcomes and value; however, drug prices have increased and pharmaceutical research and development (R&D) productivity is at its lowest. The healthcare industry and IT solutions providers are finding real-world evidence (RWE) as a potential solution to...

31 Jul 2017  |  North America  |  Market Research

US Hospital Workforce Management Software Market, Forecast to 2020

Healthcare Shifts to a Data-Driven Strategic Approach to Managing Labor

Infographics

×

Hospitals often face an intricate balancing act in delivering the right clinical, operational and administrative mix of employees to achieve multiple goals and needs of the enterprise. Connecting all the dots for proactive and on-budget workforce strategic planning is almost impossible to achieve with paper-based systems given the increasing amount...

Enterprise imaging is no longer a technology upgrade. It is becoming the operating model for imaging across the provider organization, and the next investment cycle will decide which vendors lead it. This study gives vendors, ecosystem partners, and provider leaders a 360-degree view of that shift, and it is built on primary interviews with the peo...

08 Feb 2023  |  North America  |  Market Research

Growth Opportunities in the Global Cloud-based Medical Imaging Informatics Market, Forecast to 2026

Conventional Medical Imaging Informatics Shifts to AI-based Consolidated Solutions

Infographics

×

Medical imaging informatics solution deployment is shifting from the on-premises model to a cloud-based infrastructure. The conventional on-premises model, which requires every enterprise to buy, operate, and maintain its own cumbersome IT infrastructure and solutions, proves unsustainable in the era of big data. It is also short-sighted given the ...

This study addresses the current shift from in-hospital settings to non-hospital or outpatient settings for medical imaging service providers in the US and EU. The focus is on X-ray, ultrasound, mammography, MRI, and imaging IT solutions delivered in outpatient settings, such as ambulatory surgery centers (ASCs), independent imaging diagnostic cent...

17 Mar 2020  |  North America  |  Market Research

Analysis of the Critical Care Patient Monitoring Market, US and EU5, Forecast to 2024

Market to Shift from Stand-alone Monitors to Integrated Solutions and Reach a Size of $13.17 Billion in 2024

Infographics

×

Key Issues Addressed

The economic burden for global critical care is estimated at $270 billion and intensive care unit (ICU) mortality in developed countries is still in the range of 10% to 20%. Advancements in effective patient monitoring in the ICU can not only help reduce the mortality rate but also be beneficial in improving patient and healthcare staff experience....

The global pharmaceutical research and development (R&D) pipeline accounts for more than 21,000 molecules, as of April 2023, indicating a 5.8% hike over 2022, with more than 6,100 molecules in active development. In general, however, the pharma/biopharma industry has stagnated with respect to R&D activity. Overall R&D expenditure totals about $276....